Full Text
EE303 Cost-Effectiveness Analysis of Pd-L1 Testing Associated with Pembrolizumab for First-Line Treatment of Advanced NSCLC in China

Abstract

Authors

Y. Wu L. Tao L. Chang F. Wang S. Sun H. Sam

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×